Table 4:

Prespecified exploratory analysis of efficacy endpoints by PD-L1 expression

	PD-L1 combined positive score <10				PD-L1 combined positive score ≥10
	Ramucirumab plus docetaxel (n=72)	Placebo plus docetaxel (n=63)	HR (95% CI)	p value	Ramucirumab plus docetaxel (n=57)	Placebo plus docetaxel (n=48)	HR (95% CI)	p value
Progression-free survival (months)	4·2 (2·8–5·8)	2·7 (14·2–9)	0·672 (0·451–1·001);	0·0507	5·2 (3·3–5·6)	2·8 (1·5–3·0)	0·530 (0·339–0·830)	0·0060
Overall survival (months)	8·5 (6·8–11·6)	6·9 (44·9–9)	0·999 (0·664–1·502)	0·9955	9·2 (5·4–12·7)	6·4 (3·9–7·4)	0·519 (0·331–0·816)	0·0048
Patients achieving an overall response*	18; 25% (15·0–35·0)	2; 3% (0·0–7·5)	..	<0·001	16; 28% (16·4–39·7)	6; 13% (3·1–21·9)	..	0·042
Patients achieving disease control*	45; 63% (51·3–73·7)	33; 52% (40·1–64·7)	..	0·24	41; 72% (60·3–83·6)	27; 56% (42·2–70·3)	..	0·070

Data are median (95% CI) unless otherwise indicated. PD-L1=programmed cell death 1. HR=hazard ratio.

^*Data are n; % (95% CI).